Delavarian Z, Layegh P, Pakfetrat A, Zarghi N, Khorashadizadeh M, Ghazi A. Evaluation of desmoglein 1 and 3 autoantibodies in pemphigus vulgaris: correlation with disease severity. J Clin Exp Dent. 2020;12(5):e440-5.

doi:10.4317/jced.56289

______________________________________________

References

1. Russo I, De Siena FP, Saponeri A, Alaibac M. Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission. Medicine (Baltimore). 2017;96:e8801. https://doi.org/10.1097/MD.0000000000008801 PMid:29145342 PMCid:PMC5704887

2. Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol. 2005;14:861-75. https://doi.org/10.1111/j.1600-0625.2005.00367.x PMid:16274453

3. Scully C, Challacombe SJ. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med. 2002;13:397-408. https://doi.org/10.1177/154411130201300504 PMid:12393759

4. Michailidou EZ Belazi MA, Markopoulos AK, Tsatsos MI, Mourellou ON, Antoniades DZ. Epidemiologic survey of Pemphigus Vulgaris with oral manifestations in northern Greece: Retrospective study of 129 patients. Int J Dermatol. 2007;46:356-61. https://doi.org/10.1111/j.1365-4632.2006.03044.x PMid:17442072

5. Schmidt E, Bröcker E-B, Zillikens D. Pemphigus. Loss of desmosomal cell-cell contact. Hautarzt. 2000;51:309-18. https://doi.org/10.1007/s001050051124 PMid:10875067
6. Silva D, Bernardes AG. Pemphigus: cartography on the coordination of health policies. Cien Saude Colet. 2018;23:2631-40. https://doi.org/10.1590/1413-81232018238.14892016 PMid:30137132

7. Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366:61-73. https://doi.org/10.1016/S0140-6736(05)66829-8 PMid:15993235

8. Lin N, Liu Q, Wang M, Wang Q, Zeng K. Usefulness of miRNA-338-3p in the diagnosis of pemphigus and its correlation with disease severity. Peer J. 2018;6:e5388. https://doi.org/10.7717/peerj.5388 PMid:30083474 PMCid:PMC6078064

9. Murrell DF, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. J Am Acad Dermatol. 2020;82:575-585.e1. PMid:29438767

10. Cholera M, Chainani-Wu N. Management of Pemphigus Vulgaris. Adv Ther. 2016;33:910-58. https://doi.org/10.1007/s12325-016-0343-4 PMid:27287854 PMCid:PMC4920839

11. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772-9. https://doi.org/10.1056/NEJMoa062930 PMid:17065638

12. Kumar B, Arora S, Kumaran MS, Jain R, Dogra S. Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus. Indian J Dermatol Venereol Leprol. 2006;72:203-6. https://doi.org/10.4103/0378-6323.25780 PMid:16766834

13. Hallaji Z, Mortazavi H, Lajevardi V, Tamizifar B, AmirZargar A, Daneshpazhooh M, et al. Serum and salivary desmoglein 1 and 3 enzyme-linked immunosorbent assay in pemphigus vulgaris: correlation with phenotype and severity. J Eur Acad Dermatol Venereol. 2010;24:275-80. https://doi.org/10.1111/j.1468-3083.2009.03408.x PMid:19709345

14. Sharma VK, Prasad HR, Khandpur S, Kumar A. Evaluation of desmoglein enzyme-linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgaris. Int J Dermatol. 2006;45:518-22. https://doi.org/10.1111/j.1365-4632.2006.02593.x PMid:16700783

15. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001;144:775-80. https://doi.org/10.1046/j.1365-2133.2001.04132.x PMid:11298536

16. Van ATT, Nguyen TV, Huu SN, Thi LP, Minh PPT, Huu N, et al. Improving Treatment Outcome of Pemphigus Vulgaris on Vietnamese Patients by Using Desmoglein Elisa Test. Open Access Maced J Med Sci. 2019;7:195-7. https://doi.org/10.3889/oamjms.2019.003 PMid:30745956 PMCid:PMC6364727

17. Belloni-Fortina A, Faggion D, Pigozzi B, Peserico A, Bordignon M, Baldo V, et al. Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up. Clin Dev Immunol. 2009;2009:187864. https://doi.org/10.1155/2009/187864 PMid:20049340 PMCid:PMC2798087

18. Mortazavi H, Shahdi M, Amirzargar AA, Naraghi ZS, Valikhani M, Daneshpazhooh M, et al. Desmoglein ELISA in the diagnosis of pemphigus and its correlation with the severity of pemphigus vulgaris. Iran J Allergy Asthma Immunol. 2009;8:53-6. PMid:19279360

19. De D, Khullar G, Handa S, Joshi N, Saikia B, Minz RW. Correlation between salivary and serum anti-desmoglein 1 and 3 antibody titres using ELISA and between anti-desmoglein levels and disease severity in pemphigus vulgaris. Clin Exp Dermatol. 2017;42:648-50. https://doi.org/10.1111/ced.13124 PMid:28543318

20. Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009;145:529-35. https://doi.org/10.1001/archdermatol.2009.9 PMid:19451496

21. Daneshpazhooh M, Chams-Davatchi C, Khamesipour A, Mansoori P, Taheri A, Firooz A, et al. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. J Eur Acad Dermatol Venereol. 2007;21:1319-24. https://doi.org/10.1111/j.1468-3083.2007.02254.x PMid:17958835

22. Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol. 2000;143:343-8. https://doi.org/10.1046/j.1365-2133.2000.03660.x PMid:10951143